|
Borax Combo
The Borax combo, also known by the informal brand names Blue Bliss and Pink Star, is a combination recreational and designer drug described as an MDMA-like entactogen. It is a mixture of the entactogen 5-MAPB or MDAI, the stimulant 2-fluoromethamphetamine (2-FMA), and the serotonergic psychedelic 5-MeO-MiPT or 4-HO-MET, all at specific fixed doses. Contrary to its name, the Borax combo does not contain or have anything to do with the substance borax. The Borax combo is anecdotally claimed to closely mimic the effects and "magic" of MDMA ("ecstasy"). It also appears likely to produce serotonergic neurotoxicity similarly to MDMA. The combination was first described in 2014 and has received increasing forensic and scientific attention since then. It has been encountered as a novel designer drug in the form of ecstasy-like pressed tablets under names like Blue Bliss and Pink Star. In addition, the Borax combo has received scientific interest due to its apparent ability to close ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-MAPB
5-MAPB, also known as 5-(''N''-methyl-2-aminopropyl)benzofuran, is an entactogen and designer drug of the amphetamine family that is similar to MDMA in its structure and effects. It has been patented by Tactogen as an entactogen for potential use as a medicine. Pharmacology Pharmacodynamics 5-MAPB acts as a serotonin–norepinephrine–dopamine releasing agent with values for induction of monoamine release of 64nM for serotonin, 24nM for norepinephrine, and 41nM for dopamine using rat brain synaptosomes. It is also a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. 5-MAPB has been described by Matthew Baggott as the MDMA analogue so far known that has the closest effects and so-called "magic" to MDMA itself. Other analogues that lack the full quality of MDMA include MBDB, methylone, 6-APDB, 5-APDB, 6-APB, 5-APB, MDAT, and MDAI, among others. 5-MAPB has been marketed as a less- or non-neurotoxic alternative to MDMA. However, 5-MAPB has been f ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Entactogen
Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observed and reported for experiences with MDMA. This class of drug is distinguished from the classes of hallucinogens or psychedelics and stimulants, although entactogens, for instance MDMA, can also have these properties. Entactogens are used both as recreational drugs and are being investigated for medical use in the treatment of psychiatric disorders, for instance MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Notable members of this class include MDMA, MDA, MDEA, MDOH, MBDB, 5-APB, 5-MAPB, 6-APB, 6-MAPB, methylone, mephedrone, αMT, αET, and MDAI, among others. Most entactogens are phenethylamines and amphetamines, although several, such as αMT and αET, are tryptamines. When referring to MDMA and its cou ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin–norepinephrine Releasing Agent
A serotonin–norepinephrine releasing agent (SNRA) is a type of drug which induces the release of serotonin and norepinephrine (and epinephrine) in the body and/or brain. Only a few SNRAs are known, examples of which include norfenfluramine, (''R'')-MDMA, MBDB, and MDAI. Fenfluramine produces norfenfluramine as a major active metabolite and hence is an SNRA similarly. It was formerly used as an appetite suppressant for the treatment of obesity. (''R'')-MDMA, MBDB, and MDAI are entactogens. A closely related type of drug is a serotonin–norepinephrine reuptake inhibitor Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopaus ... (SNRI). Mechanism of action See also * Monoamine releasing agent * Serotonin releasing agent * Norepinephrine releasing agent * Serotonin–dopamine ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonin–norepinephrine–dopamine Releasing Agent
A serotonin–norepinephrine–dopamine releasing agent (SNDRA), also known as a triple releasing agent (TRA), is a type of drug which induces the release of serotonin, norepinephrine/epinephrine, and dopamine in the brain and body. SNDRAs produce euphoriant, entactogen, and psychostimulant effects, and are almost exclusively encountered as recreational drugs. A closely related type of drug is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). Examples of SNDRAs Examples of SNDRAs include specific amphetamines such as MDMA, MDA, 4-methylamphetamine, methamphetamine (in high doses), certain substituted benzofurans such as 5-APB and 6-APB, naphthylisopropylamine; cathinones such as mephedrone and methylone; tryptamines such as αMT and αET; along with agents of other chemical classes such as 4,4'-DMAR, and 5-IAI.Bruce E. Blough, Richard Rothman, Antonio Landavazo, Kevin M. Page, Ann Marie Decker. Phenylmorpholines and analogues thereof. US Patent 2013/0 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Mechanism Of Action
In pharmacology, the term mechanism of action (MOA) refers to the specific biochemical Drug interaction, interaction through which a Medication, drug substance produces its pharmacological effect. A mechanism of action usually includes mention of the specific molecular targets to which the drug binds, such as an enzyme or receptor (biochemistry), receptor. Receptor sites have specific affinities for drugs based on the chemical structure of the drug, as well as the specific action that occurs there. Drugs that do not bind to receptors produce their corresponding therapeutic effect by simply interacting with chemical or physical properties in the body. Common examples of drugs that work in this way are antacids and laxatives. In contrast, a Mode of action, mode of action (MoA) describes functional or anatomical changes, at the cellular level, resulting from the exposure of a living organism to a substance. Importance Elucidating the mechanism of action of novel drugs and medicati ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Monoaminergic
Monoaminergic means "working on monoamine neurotransmitters", which include serotonin, dopamine, norepinephrine, epinephrine, and histamine. A monoaminergic, or monoaminergic drug, is a chemical, which functions to directly modulate the serotonin, dopamine, norepinephrine, epinephrine, and/or histamine neurotransmitter systems in the brain. Monoaminergics include catecholaminergics (which can be further divided into adrenergics and dopaminergics), serotonergics, and histaminergics. Examples of monoaminergic drugs include monoamine precursors, monoamine receptor modulators, monoamine reuptake inhibitors, monoamine releasing agents, and monoamine metabolism modulators such as monoamine oxidase inhibitors. See also * Adenosinergic * Adrenergic * Cannabinoidergic * Cholinergic * Dopaminergic * GABAergic * Glycinergic * Histaminergic * Melatonergic A melatonergic agent (or drug) is a chemical which functions to directly modulate the melatonin system in the body or brain. Exam ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Serotonergic Neurotoxin
A monoamine neurotoxin, or monoaminergic neurotoxin, is a drug that selectively damages or destroys monoaminergic neurons. Monoaminergic neurons are neurons that signal via stimulation by monoamine neurotransmitters including serotonin, dopamine, and norepinephrine. Examples of monoamine neurotoxins include the serotonergic neurotoxins ''para''-chloroamphetamine (PCA), methylenedioxymethamphetamine (MDMA), and 5,7-dihydroxytryptamine (5,7-DHT); the dopaminergic neurotoxins oxidopamine (6-hydroxydopamine), MPTP, and methamphetamine; and the noradrenergic neurotoxins oxidopamine and DSP-4. In the case of serotonergic neurotoxins like MDMA, research suggests that simultaneous induction of serotonin and dopamine release, serotonin depletion, dopamine uptake and metabolism, hyperthermia, oxidative stress and antioxidant depletion, and/or drug metabolites may all be involved in the neurotoxicity. On the other hand, there is evidence that drug metabolites may not be involved. So ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
